Featured Research

from universities, journals, and other organizations

FDA Approves New Oral Rinse To Help Treat Gingivitis

Date:
April 21, 2005
Source:
U.S. Food And Drug Administration
Summary:
The Food and Drug Administration (FDA) today approved a new prescription treatment for gingivitis, a common gum disease that affects most adults at some point in their lives. The Decapinol Oral Rinse treats gingivitis by reducing the number of bacteria that attach to tooth surfaces and cause dental plaque.

The Food and Drug Administration (FDA) today approved a new prescription treatment for gingivitis, a common gum disease that affects most adults at some point in their lives. The Decapinol Oral Rinse treats gingivitis by reducing the number of bacteria that attach to tooth surfaces and cause dental plaque. Decapinol is approved for use in persons 12 years of age or older when routine oral hygiene is not adequate to prevent gingivitis. Decapinol is not recommended for use by pregnant women.

"This new dental rinse helps treat gingivitis when tooth brushing and flossing are not enough," said Dr. Daniel Schultz, Director of FDA's Center for Devices and Radiological Health. "This product can lead to a substantial reduction in gingivitis."

Gingivitis is an inflammation of the gums that often appears as swollen, red, or bleeding gums. Scientists believe plaque-forming bacteria that live in the mouth and on tooth surfaces are a cause of gingivitis. Substances released by the bacteria cause the gum inflammation. Reduction of plaque bacteria can decrease the inflammatory substances and cause a reduction in gingivitis.

Clinical studies were conducted in adults with mild to severe gingivitis. In these studies, Decapinol was compared either to "no treatment" or to an antimicrobial rinse. The studies showed that Decapinol decreases gingivitis up to 60%--compared to no treatment and when used as instructed with recommended brushing and flossing.

Decapinol Oral Rinse is being regulated as a medical device and not as a drug because its primary mode of action is to create a physical barrier, rather than to act chemically. Decapinol contains a substance called a surfactant that acts as a physical barrier, making it harder for bacteria to stick to tooth surfaces. FDA also has approved a number of other anti-gingivitis oral rinses, but since these products act chemically to kill bacteria that live in the mouth, they are regulated as antimicrobial drugs rather than as devices.

Decapinol Oral Rinse is manufactured by Sinclair Pharmaceuticals Limited, based in the United Kingdom.


Story Source:

The above story is based on materials provided by U.S. Food And Drug Administration. Note: Materials may be edited for content and length.


Cite This Page:

U.S. Food And Drug Administration. "FDA Approves New Oral Rinse To Help Treat Gingivitis." ScienceDaily. ScienceDaily, 21 April 2005. <www.sciencedaily.com/releases/2005/04/050419111800.htm>.
U.S. Food And Drug Administration. (2005, April 21). FDA Approves New Oral Rinse To Help Treat Gingivitis. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2005/04/050419111800.htm
U.S. Food And Drug Administration. "FDA Approves New Oral Rinse To Help Treat Gingivitis." ScienceDaily. www.sciencedaily.com/releases/2005/04/050419111800.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins